In Vivo Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone
RWJ-416457

Jamese J. Hilliard,* Jeffrey Fernandez, John Melton, Mark J. Macielag,† Raul Goldschmidt,‡
Karen Bush,# and Darren Abbanat

Received 24 June 2008/Returned for modification 6 January 2009/Accepted 26 February 2009

RWJ-416457 is an investigational pyrrolopyrazolyl-substituted oxazolidinone with activity against antibiotic-susceptible and -resistant gram-positive pathogens. Efficacies of RWJ-416457, linezolid, and vancomycin against methicillin-susceptible Staphylococcus aureus (MSSA) and community-associated methicillin-resistant S. aureus (CA-MRSA) in murine skin and systemic infections were compared, as were efficacies against Streptococcus pneumoniae in a lower respiratory infection. In staphylococcal systemic infections, RWJ-416457 was equipotent with to twofold more potent than linezolid, with 50% effective dose values ranging from 1.5 to 5 mg/kg of body weight/day. RWJ-416457 was two- to fourfold less potent than vancomycin against MSSA but up to fourfold more potent than vancomycin against CA-MRSA. In MSSA and CA-MRSA skin infections, RWJ-416457 demonstrated an efficacy similar to that of linezolid, reducing CFU/g skin approximately 1.0 log10 at all doses tested; vancomycin yielded greater reductions than the oxazolidinones, with decreases in CFU/g skin of 3 log10 (MSSA) and 2 log10 (CA-MRSA). In the pneumococcal model, RWJ-416457 was two- to fourfold more potent than linezolid. The free-drug area under the concentration-time curves at 24 h (fAUC24h) were similar for RWJ-416457 and linezolid. The half-life of RWJ-416457 was up to threefold longer than that of linezolid for all routes of administration. The fAUC24h/MIC ratio, the pharmacodynamic parameter considered predictive of oxazolidinone efficacy, was approximately twofold greater for RWJ-416457 than for linezolid.

Since the fAUC values were similar for both compounds, the higher AUC/MIC ratios of RWJ-416457 appear to result from its greater in vitro potency. These results demonstrate that RWJ-416457 is a promising new oxazolidinone with efficacy in S. aureus or S. pneumoniae mouse infection models.

The increasing incidence of antibiotic resistance among pathogenic bacteria threatens the utility of existing antibiotics, resulting in the need for new antibiotics with efficacy against susceptible and resistant isolates (21). Staphylococcus aureus, once largely susceptible to antibiotics, is now often resistant to multiple classes, including β-lactams, macrolides, aminoglycosides, and fluoroquinolones (5, 32). Methicillin-resistant S. aureus (MRSA), defined by resistance to oxacillin, contains the mecA gene, providing resistance to all available β-lactams (3, 6, 19). Historically, these multiresistant MRSA isolates have been found predominantly in hospitals and health care facilities, whereas community-associated strains remained largely methicillin susceptible. In a recent development, methicillin resistance has been found increasingly in community-associated S. aureus, resulting from the acquisition of an abbreviated version of the mec element type IV (4, 25, 26). These community-associated MRSA (CA-MRSA) strains, first described in 1981 and responsible for recent outbreaks in diverse settings and groups, such as schools, prisons, athletic teams, the homeless, drug users, and the military (7, 15, 17, 23, 27, 31), are usually involved in skin disease but have also been linked to lethal pneumonia and sepsis (18, 25, 31).

Although many CA-MRSA isolates are also resistant to erythromycin and, by some reports, fluoroquinolones, to date CA-MRSA strains remain susceptible to a variety of other antibiotic classes (10, 19, 31). Notably, with increased exposure of CA-MRSA to antibiotics, increasing resistance to tetracyclines and clindamycin has been reported (10, 20, 31).

To address the need for new oral agents effective in the treatment of CA-MRSA as well as health care-associated MRSA, the novel oxazolidinone RWJ-416457 was identified. This compound has a spectrum of activity similar to that of linezolid, the sole regulatory agency-approved representative of the oxazolidinone class, against antibiotic-susceptible and -resistant gram-positive pathogens, including MRSA, vancomycin-resistant enterococci, and penicillin-resistant pneumococci (11, 29). RWJ-416457 MICs are two- to fourfold lower than those of linezolid against relevant gram-positive clinical pathogens, including health care-associated MRSA and CA-MRSA strains (13, 22). Thus, RWJ-416457, in phase 1 development for the treatment of respiratory tract and skin and skin structure infections, may represent a viable option for patients, including those unable to tolerate β-lactams or macrolides.

We report herein on the in vivo activities of RWJ-416457, linezolid, and vancomycin (Fig. 1) in S. aureus and Streptococcus pneumoniae murine models of infection and on selected pharmacokinetic and pharmacodynamic parameters.
Materials and Methods

Bacterial strains. Methicillin-susceptible S. aureus (MSSA) ATCC 13709 and penicillin-susceptible S. pneumoniae (PSP) ATCC 6081 were obtained from the American Type Culture Collection. OC8525, a CA-MRSA strain, was a gift from B. Kreiswirth (Public Health Research Institute, Newark, NJ).

Compound preparation. RWJ-416457 was synthesized at Johnson & Johnson Pharmaceutical Research and Development. Vancomycin was purchased from MP Biomedicals, Inc. (Irvine, CA), and linezolid was obtained from Pfizer (Groton, CT). RWJ-416457 was prepared as a suspension in 0.5% Methocel for oral (p.o.) dosing. For subcutaneous (s.c.)- and intravenous (i.v.)-dosage forms, mice were given a single p.o., s.c., or i.v. dose of RWJ-416457 or linezolid. Infected mice not treated with drug served as controls. Mortality was monitored for 48 h postinfection. At least two independent studies, with five to eight mice per dose group, were conducted. The ED50 was calculated as described above.

Staphylococcal systemic lethal infection. In the mouse systemic infection model with the S. aureus strains ATCC 13709 (MSSA) and OC8525 (CA-MRSA), the effects of RWJ-416457 were similar to and up to 5.7-fold more potent than the effects of linezolid (Table 1) when dosed p.o. or parenterally, with ED50 values ranging from 1.5 to 4.7 mg/kg/day for RWJ-416457 and 3.7 to 8.5 mg/kg/day for linezolid. Although ED50 values for RWJ-416457 were generally lower than those for linezolid, the 95% fiducial limits frequently overlapped. Vancomycin demonstrated lower ED50 values than the oxazolidinones against the MSSA strain but was generally less potent in the CA-MRSA model.

Staphylococcal skin infection studies. The efficacies of RWJ-416457, linezolid, and vancomycin against S. aureus Smith ATCC 13709 (MSSA) were summarized in Fig. 2. In untreated control animals, the MSSA CFU increased 1.9 log10 relative to the level for the initial inoculum. Treatment of the infected skin with RWJ-416457 at doses of 5 mg/kg/day resulted in approximately a 0.9-log10 decrease in CFU/g skin relative to the level for the initial inoculum. At a dose of 5 mg/kg/day of RWJ-416457, no effect on growth of the MSSA strain was observed, with CFU values similar to those for untreated control animals. At a dose of 20 mg/kg/day, RWJ-416457 exhibited static activity, with CFU remaining the same relative to the level for the initial inoculum. Similar results were obtained with linezolid (doses of 5 mg/kg/day to 320 mg/kg).

Results

In vitro susceptibilities. The in vitro activities of RWJ-416457, linezolid, and vancomycin against the S. aureus and S. pneumoniae strains used in the infection models are shown in Table 1. RWJ-416457 was twofold more potent than linezolid against the tested isolates. Vancomycin MICs against the MSSA and MRSA strains were similar to those of RWJ-416457.

Staphylococcal systemic lethal infection. In the mouse systemic infection model with the S. aureus strains ATCC 13709 (MSSA) and OC8525 (CA-MRSA), the effects of RWJ-416457 were similar to and up to 5.7-fold more potent than the effects of linezolid (Table 1) when dosed p.o. or parenterally, with ED50 values ranging from 1.5 to 4.7 mg/kg/day for RWJ-416457 and 3.7 to 8.5 mg/kg/day for linezolid. Although ED50 values for RWJ-416457 were generally lower than those for linezolid, the 95% fiducial limits frequently overlapped. Vancomycin demonstrated lower ED50 values than the oxazolidinones against the MSSA strain but was generally less potent in the CA-MRSA model.

Staphylococcal skin infection studies. The efficacies of RWJ-416457, linezolid, and vancomycin against S. aureus Smith ATCC 13709 (MSSA) were summarized in Fig. 2. In untreated control animals, the MSSA CFU increased 1.9 log10 above the infecting inoculum level to 8.2 log10 CFU/g skin in 48 h. In contrast, during this same time period, treatment of S. aureus Smith with RWJ-416457 at doses of 5 mg/kg/day resulted in approximately a 0.9-log10 decrease in CFU/g skin relative to the level for the initial inoculum. At a dose of 5 mg/kg/day of RWJ-416457, no effect on growth of the MSSA strain was observed, with CFU values similar to those for untreated control animals. At a dose of 20 mg/kg/day, RWJ-416457 exhibited static activity, with CFU remaining the same as the level for the initial inoculum. Similar results were observed with linezolid (doses from 5 mg/kg/day to 320 mg/kg).
day) and vancomycin (doses from 1.6 mg/kg/day to 25 mg/kg/ day). At 100 mg/kg/day, vancomycin was more potent than either oxazolidinone, decreasing CFU/g skin by 3 log_{10}.

The efficacies of RWJ-416457, linezolid, and vancomycin against the CA-MRSA strain are summarized in Fig. 3. In control animals, the bacteria grew 1.6 log_{10} CFU from the level for the initial inoculum over the 48-h treatment period. In animals treated with RWJ-416457, CFU in the skin remained unchanged relative to the level for the initial inoculum (dose of 5 mg/kg/day) or decreased approximately 1 log_{10} CFU/g skin tissue (doses of 20 to 320 mg/kg/day). Similar results were obtained for linezolid, with decreases of 0.5 to 1.3 log_{10} CFU/g skin over the same dose range. Vancomycin treatments at 6.2 and 25 mg/kg/day had a minimal effect on MRSA skin titers, which remained above those for the initial inoculum. The highest doses of vancomycin (100 and 400 mg/kg/day) resulted in decreases that were 1.5 and 2 log_{10} CFU/g skin tissue, respectively, the largest decreases observed for any of the MRSA treatment groups.

**Pneumococcal lower respiratory infection.** In the lethal lower respiratory infection model with *S. pneumoniae* ATCC 6301, RWJ-416457 was at least 2- to 4.5-fold more potent than linezolid (Table 1) across the different routes of administration, with ED_{50} values ranging from 3.1 to 18 mg/kg/day for RWJ-416457 and 14 to 40 mg/kg/day for linezolid. In this model, for both oxazolidinones, potency appeared to decrease when the compounds were dosed parenterally, with the highest ED_{50} values observed with i.v. dosing.

**Single-dose pharmacokinetics.** The plasma pharmacokinetic parameters for RWJ-416457 and linezolid are shown in Fig. 4 and 5 and in Table 2. Both total and free-drug values for the area under the concentration-time curve at 24 h (AUC_{24} and

---

**TABLE 1. In vitro and in vivo activities of RWJ-416457, linezolid, and vancomycin against gram-positive pathogens in mouse lethal infection models**

<table>
<thead>
<tr>
<th>Model and strain (type)</th>
<th>Compound</th>
<th>MIC (µg/ml)</th>
<th>ED_{50}, mg/kg/day (95% fiducial limit)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>p.o.</td>
</tr>
<tr>
<td><em>S. aureus</em> systemic infection models</td>
<td>RWJ-416457</td>
<td>1</td>
<td>3.4 (2.7–4.5)</td>
</tr>
<tr>
<td>ATCC 13709 (MSSA)</td>
<td>Linezolid</td>
<td>2</td>
<td>6.4 (5.2–7.8)</td>
</tr>
<tr>
<td></td>
<td>Vancomycin</td>
<td>1</td>
<td>NA*</td>
</tr>
<tr>
<td>OC8525 (CA-MRSA)</td>
<td>RWJ-416457</td>
<td>2</td>
<td>2.1 (1.3–3.0)</td>
</tr>
<tr>
<td></td>
<td>Linezolid</td>
<td>4</td>
<td>5.1 (2.7–7.8)</td>
</tr>
<tr>
<td></td>
<td>Vancomycin</td>
<td>1</td>
<td>NA</td>
</tr>
<tr>
<td><em>S. pneumoniae</em> lung infection model</td>
<td>RWJ-416457</td>
<td>1</td>
<td>3.1 (2.0–4.9)</td>
</tr>
<tr>
<td>ATCC 6301 (PSSP)</td>
<td>Linezolid</td>
<td>2</td>
<td>14 (9.5–28)</td>
</tr>
</tbody>
</table>

*NA, not applicable.*
AUC24, respectively) and the maximum concentration of drug in serum (Cmax and fCmax, respectively) were determined (Table 2). The fAUC24 values of RWJ-416457 ranged from 8 to 13 h \cdot \mu g/ml (with the i.v. value normalized to a dose of 10 mg/kg/day, assuming a linear response) and were similar to those of linezolid for all three dosing routes. fCmaxs for RWJ-416457 were comparable to those for linezolid following i.v. dosing but were 1.7-fold and 3.2-fold lower than those for linezolid when dosed s.c. and p.o., respectively. RWJ-416457 time to maximum concentration of drug in serum values (s.c. and p.o. dosing) were 0.5 and 2 h, at least 4- and 16-fold longer, respectively, than those for linezolid. The half-life (t1/2) of RWJ-416457, 1.5 to 2 h when dosed parenterally and 3.4 h when dosed p.o., was 2.4- to 3-fold longer than that of linezolid. In agreement with the longer t1/2 of RWJ-416457, clearance (CL) values for RWJ-416457 when dosed i.v. were slightly lower than those for linezolid (Table 2). When CL was adjusted for bioavailability, values for both compounds (p.o. or s.c.) were similar.

Pharmacodynamic analyses. The AUC24/MIC ratios were calculated for the data in this study (Table 3) to determine whether the relative magnitudes for RWJ-416457 and linezolid were consistent with the results observed in these efficacy studies. When i.v. data were normalized to a 10-mg/kg dose and compared with data for the other routes of administration, the fAUC24/MIC ratios for RWJ-416457 ranged from 4.1 to 13, whereas those for linezolid were 1.8 to 6.6. The greater fAUC/MICs for RWJ-416457 than for linezolid are similar to the relative differences in the ED50 values of RWJ-416457 and linezolid described above for the animal infection models.

DISCUSSION

The oxazolidinone class of antibiotics has been developed to address the need for new agents to treat antibiotic-susceptible and -resistant gram-positive pathogens, such as MRSA and PRSP, in health care and community settings. RWJ-416457 has previously been described as an investigational oxazolidinone with more potent in vitro activity against selected gram-positive pathogens than linezolid (13, 22). In this study, we report on the pharmacokinetics, pharmacodynamics, and efficacy of RWJ-416457 in experimental mouse models.

In these murine models, ED50 values for RWJ-416457 were generally lower than those for linezolid across all models and dosing routes. These in vivo results are consistent with the twofold- to fourfold-lower MICs of RWJ-416457 for the strains used in this study. However, because 95% fiducial limits frequently overlapped, it is possible that some ED50 values were comparable.

While the trends between in vitro and in vivo potencies were maintained in comparisons of RWJ-416457 and linezolid, inconsistencies were observed when comparing the in vitro and in vivo potencies between the MSSA and CA-MRSA models. Although MICs of RWJ-416457 and linezolid were twofold higher with the CA-MRSA strain than with the MSSA strain, ED50 values were generally equivalent or lower in the CA-MRSA model. This may reflect differences in virulence of the MSSA and CA-MRSA strains. Similarly, whereas the vancomycin MICs were equivalent for the MSSA and CA-MRSA strains, the in vivo efficacy of vancomycin in the CA-MRSA systemic model was reduced relative to that in the MSSA systemic model. Notably, the in vivo inoculum of CA-MRSA was 1.5 log10 CFU higher than that used in the MSSA model; these data are consistent with the reported phenomenon that an increased vancomycin inoculum can selectively decrease the in vivo efficacy relative to in vitro potency (9). The ED50 values reported for linezolid in this study are similar to those described by other investigators using systemic murine infection models, where ED50 values for S. aureus ranged from 2.9 to 7.0 mg/kg (14, 30). The improved in vivo potency of RWJ-416457 may be important clinically for the treatment of staphylococcal infections.
and enterococcal infections where MICs of linezolid approach nonsusceptibility breakpoints.

RWJ-416457 showed an oral efficacy similar to that of linezolid in the reduction of MSSA and MRSA CFU in skin infections in mice; however, at doses of ≥100 mg/kg/day, vancomycin appeared to be more effective than the oxazolidinones in this model. The oxazolidinones are bacteriostatic, whereas vancomycin can be bactericidal against some staphylococcal infections, consistent with these results. In earlier studies (12) evaluating MSSA or MRSA skin lesion size, consistent with these results. In earlier studies (12) evaluating MSSA or MRSA skin lesion size, consistent with these results. In earlier studies (12) evaluating MSSA or MRSA skin lesion size, consistent with these results. In earlier studies (12) evaluating MSSA or MRSA skin lesion size, consistent with these results.

TABLE 2. Plasma pharmacokinetic parameters for RWJ-416457 and linezolid in CF-1 mice

<table>
<thead>
<tr>
<th>Compound</th>
<th>Administration route</th>
<th>Dose (mg/kg)</th>
<th>AUC24 (g/ml)</th>
<th>fAUC24 (g/ml)</th>
<th>Cmax (µg/ml)</th>
<th>fCmax (µg/ml)</th>
<th>Tmax (h)</th>
<th>t½ (h)</th>
<th>CL (ml/h/kg)</th>
<th>CL/F (%) (ml/h/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RWJ-416457</td>
<td>i.v.</td>
<td>2</td>
<td>3.2</td>
<td>1.7</td>
<td>4.4</td>
<td>2.4</td>
<td>NA</td>
<td>1.5</td>
<td>630</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>i.v.</td>
<td>2</td>
<td>2.1</td>
<td>1.4</td>
<td>3.3</td>
<td>2.3</td>
<td>NA</td>
<td>0.5</td>
<td>940</td>
<td></td>
</tr>
<tr>
<td>RWJ-416457</td>
<td>s.c.</td>
<td>10</td>
<td>15</td>
<td>8.3</td>
<td>7.5</td>
<td>4.1</td>
<td>0.5</td>
<td>2.0</td>
<td>650</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>s.c.</td>
<td>10</td>
<td>16</td>
<td>11</td>
<td>11</td>
<td>7.1</td>
<td>≤0.13</td>
<td>0.8</td>
<td>640</td>
<td></td>
</tr>
<tr>
<td>RWJ-416457</td>
<td>p.o.</td>
<td>10</td>
<td>23</td>
<td>13</td>
<td>3.5</td>
<td>1.9</td>
<td>2.0</td>
<td>3.4</td>
<td>430</td>
<td></td>
</tr>
<tr>
<td>Linezolid</td>
<td>p.o.</td>
<td>10</td>
<td>19</td>
<td>13</td>
<td>8.9</td>
<td>6.0</td>
<td>≤0.13</td>
<td>1.4</td>
<td>520</td>
<td></td>
</tr>
</tbody>
</table>

a The free-drug plasma exposure following a single 10-mg/kg dose (p.o. and s.c.) or a single 2-mg/kg dose (i.v.) was determined from the total drug plasma levels corrected for protein binding.

b Tmax, time to maximum concentration of drug in serum.

c CL/F, CL adjusted for bioavailability.

d Normalization of i.v. values to a 10-mg/kg dose (assuming linear response) yielded RWJ-416457 and linezolid AUC24 values of 16 and 11 h · µg/ml, respectively, and fAUC24 values of 8.5 and 7 h · µg/ml, respectively.

e NA, not applicable.

A mouse pharmacokinetic/pharmacodynamic study by Andes et al. (2) reported s.c. static-dose AUC24/MIC ratios of linezolid from 22 to 97 for S. pneumoniae strains and from 38 to 167 for S. aureus strains. Normalization of these ratios in the Andes et al. study to a 10-mg/kg dose, with 68% free drug (32% mouse protein binding), yielded ratios for the S. pneumoniae strains ranging from 6.3 to 12.6 and ratios for the S. aureus strains ranging from 2.4 to 9.5; these values are similar to the S. pneumoniae and S. aureus fAUC24/MICs of 5.3 and 2.6, respectively (s.c. dosing), reported for linezolid in the current study (Table 3). A single linezolid dose of 600 mg in humans (equivalent to 8.6 mg/kg) is similar to the 10-mg/kg dose administered to mice in this study. In previously published reports, linezolid single-dose AUC values (i.v.) for humans were approximately five- to sevenfold higher than the single-dose AUC values (i.v.) reported in this study for mice, and, consistently, CL in humans was approximately five- to eightfold slower than CL in mice (1, 24). With a linezolid MIC of 4 µg/ml, the calculated AUC/MIC ratio would be approximately five- to sevenfold higher in humans than in mice.

In our studies, the RWJ-416457 and linezolid p.o. AUCs were approximately 1.5-fold higher than the respective dose-adjusted i.v. AUC values (Table 2), suggesting that oral bioavailability of the oxazolidinones exceeded 100%. In general, increased exposure with p.o. or s.c. dosing did not correlate

TABLE 3. Plasma pharmacodynamic fAUC/MIC parameters for RWJ-416457 and linezolid

<table>
<thead>
<tr>
<th>Strain (type)</th>
<th>Compound</th>
<th>MIC (µg/ml)</th>
<th>fAUC24/MIC</th>
<th>fAUC24/MIC*</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. aureus ATCC 13709 (MSSA)</td>
<td>RWJ-416457</td>
<td>1</td>
<td>13</td>
<td>8.3</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Linezolid</td>
<td>2</td>
<td>6.6</td>
<td>5.3</td>
</tr>
<tr>
<td>S. aureus OC8525 (CA-MRSA)</td>
<td>RWJ-416457</td>
<td>2</td>
<td>6.3</td>
<td>4.1</td>
</tr>
<tr>
<td>Linezolid</td>
<td>4</td>
<td>3.3</td>
<td>2.6</td>
<td>1.8</td>
</tr>
<tr>
<td>S. pneumoniae ATCC 6301 (PSSP)</td>
<td>RWJ-416457</td>
<td>1</td>
<td>13</td>
<td>8.3</td>
</tr>
<tr>
<td>Linezolid</td>
<td>2</td>
<td>6.6</td>
<td>5.3</td>
<td>3.6</td>
</tr>
</tbody>
</table>

a The free-drug plasma exposure following a single 10-mg/kg dose (p.o. and s.c.) or a single 2-mg/kg dose (i.v.) was determined from the total drug plasma levels corrected for protein binding.

b The i.v. fAUC24/MIC ratios were determined from fAUC24 values projected for a 10-mg/kg i.v. dose.
with increased efficacy. This lack of correlation may be explained by differences in metabolism or CL of the oxazolidinones with the lower i.v. dose or by rate-limiting absorption following p.o. or s.c. dosing. Nonetheless, when RWJ-416457 and linezolid were compared, trends in pharmacokinetic and pharmacodynamic parameters were consistent with efficacy values observed in the systemic infection models.

In addition to the improved in vitro potency of RWJ-416457 relative to that of linezolid, RWJ-416457 MICs were similar to or lower than those of vancomycin against vancomycin-susceptible and -resistant gram-positive pathogens (13), suggesting that the potency, as well as the spectrum of activity, of RWJ-416457 is appropriate for the treatment of antibiotic-susceptible and -resistant gram-positive pathogens. The murine infection studies described herein demonstrate that RWJ-416457 has in vivo activity that is consistent with its in vitro potency, relative to these two important clinical agents. RWJ-416457, like linezolid, was effective in the treatment of staphylococcal murine skin infections, further supporting the clinical evaluation of RWJ-416457 for the treatment of skin and skin structure infections.

ACKNOWLEDGMENT
We thank Steven Stryker for technical assistance in conducting in vivo studies.

REFERENCES